Found: 21
Select item for more details and to access through your institution.
PRX005, a novel anti‐MTBR tau monoclonal antibody: results from a first‐in‐human double‐blind, placebo‐controlled, single ascending dose phase 1 study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.074181
- By:
- Publication type:
- Article
O1‐09‐05: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P241, doi. 10.1016/j.jalz.2018.06.2382
- By:
- Publication type:
- Article
O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P240, doi. 10.1016/j.jalz.2018.06.2379
- By:
- Publication type:
- Article
O1‐09‐04: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION (OLE) OF THE MARGUERITE ROAD STUDY IN PATIENTS WITH MILD ALZHEIMER'S DISEASE (AD) AFTER APPROXIMATELY TWO YEARS OF STUDY DURATION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P241, doi. 10.1016/j.jalz.2018.06.2381
- By:
- Publication type:
- Article
O1‐09‐03: 24‐MONTH AMYLOID PET RESULTS OF THE GANTENERUMAB HIGH‐DOSE OPEN LABEL EXTENSION STUDIES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P240, doi. 10.1016/j.jalz.2018.06.2380
- By:
- Publication type:
- Article
O1‐02‐03: DIAN‐TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P216, doi. 10.1016/j.jalz.2018.06.2338
- By:
- Publication type:
- Article
A 12-Month Prospective, Observational Study of Treatment Regimen and Quality of Life Associated With ADHD in Central and Eastern Europe and Eastern Asia.
- Published in:
- Journal of Attention Disorders, 2012, v. 16, n. 1, p. 44, doi. 10.1177/1087054710381480
- By:
- Publication type:
- Article
Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
- Published in:
- 2007
- By:
- Publication type:
- Correction Notice
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
- Published in:
- Nature Medicine, 2007, v. 13, n. 9, p. 1102, doi. 10.1038/nm1632
- By:
- Publication type:
- Article
APPROACHES TO SUBJECT RETENTION IN A PHASE 3 DELAY-OF-ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (MCI-AD) CLINICAL TRIAL: THE TOMMORROW STUDY EXPERIENCE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P259, doi. 10.1016/j.jalz.2017.06.126
- By:
- Publication type:
- Article
COMPARATIVE LONGITUDINAL CHANGE OF FUNCTIONAL CONNECTIVITY, DIFFUSION AND STRUCTURAL MRI MARKERS IN A PRODROMAL/MILD ALZHEIMER’S DISEASE POPULATION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1100, doi. 10.1016/j.jalz.2016.06.2291
- By:
- Publication type:
- Article
CHARACTERIZATION OF THE SCREENED POPULATION FOR THE TOMMORROW STUDY: A PHARMACOGENETICS-SUPPORTED CLINICAL TRIAL TO DELAY THE ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1184, doi. 10.1016/j.jalz.2016.07.129
- By:
- Publication type:
- Article
COMPARATIVE LONGITUDINAL CHANGE OF FUNCTIONAL CONNECTIVITY, DIFFUSION AND STRUCTURAL MRI MARKERS IN A PRODROMAL/MILD AD POPULATION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P84, doi. 10.1016/j.jalz.2016.06.141
- By:
- Publication type:
- Article
BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs)
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPP-alpha and sAPP-beta
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Optimal combination of biomarkers for predicting MCI to AD conversion selected using a bayesian framework
- Published in:
- 2010
- By:
- Publication type:
- Abstract
Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
- Published in:
- European Child & Adolescent Psychiatry, 2010, v. 19, n. 1, p. 57, doi. 10.1007/s00787-009-0042-7
- By:
- Publication type:
- Article
Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 2, p. 600, doi. 10.1111/bcp.14975
- By:
- Publication type:
- Article
Measuring cognition and function in the preclinical stage of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2018, v. 4, n. 1, p. 64, doi. 10.1016/j.trci.2018.01.003
- By:
- Publication type:
- Article
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor.
- Published in:
- Journal of Neuroscience, 2011, v. 31, n. 46, p. 16507, doi. 10.1523/JNEUROSCI.3647-11.2011
- By:
- Publication type:
- Article